Results 81 to 90 of about 47,525 (299)
Clinical Pharmacology in Drug Development, EarlyView.Abstract Aripiprazole once‐monthly (AOM) is approved for the maintenance monotherapy treatment of bipolar I disorder (BP‐I) in adults. A previously developed population pharmacokinetic model was validated by applying it to data from patients diagnosed with BP‐I.
Xiaofeng Wang +10 more
wiley +1 more source
Egyptian Journal of Medical Human Genetics, 2022 Background Tamoxifen, a selective estrogen receptor modulator, is indicated for breast cancer developed in response to estrogen. Findings In the current study we explored the relationship between the different variants of CYP2D6, CYP2C19, CYP3A5 and ...
Amira Boucenna +6 more
doaj +1 more source
CYP2D6 genotype and tamoxifen response [PDF]
Breast Cancer Research, 2005 We read with interest the article by Wegman and coworkers [1] entitled 'Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients'. The authors conducted a retrospective analysis of a tamoxifen adjuvant clinical trial and reported that a small subset of patients with estrogen receptor (ER)-positive breast ...
James N. Ingle +7 more
openaire +2 more sources
Clinical Pharmacology &Therapeutics, EarlyView.Accurate prediction of oral drug absorption in humans is essential for early drug development; however, physiologically relevant human models are lacking. This study aims to comprehensively assess the EpiIntestinal™, a human primary intestinal 3D model, for its ability to predict oral absorption (Fa), intestinal availability (Fg), CYP3A4 induction, and
Paresh P. Chothe +4 more
wiley +1 more source
CYP2D6 drug-gene and drug-drug-gene interactions among patients prescribed pharmacogenetically actionable opioids [PDF]
, 2017 Purpose When codeine and tramadol are used for pain management, it is imperative that nurses are able to assess for potential drug-gene and drug-drug-gene interactions that could adversely impact drug metabolism and ultimately pain relief.
Broome, Marion E. +6 more
core +1 more source
Clinical Pharmacology &Therapeutics, EarlyView.This study assessed the use of 35 pharmacogenomic (PGx) medications listed in the Royal College of Pathologists of Australasia (RCPA) guideline, estimated the potential costs of subsidizing PGx testing in Australia, and predicted related prescribing changes.
Bella D. Ianni +3 more
wiley +1 more source
Tailoring therapy for heart failure: the pharmacogenomics of adrenergic receptor signaling. [PDF]
, 2014 Heart failure is one of the leading causes of mortality in Western countries, and β-blockers are a cornerstone of its treatment. However, the response to these drugs is variable among individuals, which might be explained, at least in part, by genetic ...
Barrese, V +3 more
core +2 more sources
Estrogen-Induced Cholestasis Leads to Repressed CYP2D6 Expression in CYP2D6-Humanized Mice [PDF]
Molecular Pharmacology, 2015 Cholestasis activates bile acid receptor farnesoid X receptor (FXR) and subsequently enhances hepatic expression of small heterodimer partner (SHP). We previously demonstrated that SHP represses the transactivation of cytochrome P450 2D6 (CYP2D6) promoter by hepatocyte nuclear factor (HNF) 4α.
Hyunyoung Jeong, Xian Pan
openaire +3 more sources
Clinical Pharmacology &Therapeutics, EarlyView.CYP2D6 alleles with low frequency in Eurocentrically biased study populations are often excluded from pharmacogenetic investigation and consequently may have misassigned activity values. This health inequity may be contributing to imprecise dose predictions for CYP2D6‐metabolizing drugs.
Oyinlade Kehinde +6 more
wiley +1 more source
PHARMACOGENETIC FEATURES OF THERAPY OF PATIENTS WITH ATHEROSCLEROSIS
Архивъ внутренней медицины, 2018 The complexity of therapy of lipid metabolism disorders is not only in comorbidity and polypragmasia, but also in predicting a genetically determined response to the treatment.
A. L. Khokhlov +7 more
doaj +1 more source